Quantcast

EUCODIS Bioscience Receives EUR 2 Million Cash Injection to Enlarge Product Portfolio and Develop International Markets

February 3, 2010

VIENNA, Austria, February 3 /PRNewswire/ — EUCODIS Bioscience, a company
providing customized enzymes to the pharmaceutical, chemical, and other
industries, announced today that it has received a cash injection of EUR 2
million
from existing shareholders.

The Company will use these funds to swiftly add new enzyme families to
its product portfolio and to accelerate the development of international
markets. At the same time, EUCODIS Bioscience is expanding its manufacturing
capacity in pace with growing customer demand for its novel enzymes.

Commenting on the capital injection Thomas Fischer, CEO of EUCODIS
Bioscience, said: “Following several product launches in 2009 and the recent
expansion of our lipases family to 20 enzymes we continue to build our order
book. Accordingly, our revenues will finance a good part of our expenses and
investments this year.”

Fischer continued: “Given the wealth of business opportunities in front
of us, we are extremely pleased that the cash injection will help us to
broaden our product range and to ramp up our sales and marketing efforts.”

EUCODIS Bioscience’ shareholders Pontis Capital, Wiener Wachstumsfonds,
IBG, and ARAX participated in the cash injection.

Harald Schuerz, Managing Director of Wiener Wachstumsfonds, commented:
“We are delighted that the market clearly confirms the business model of
EUCODIS Bioscience. The commercial focus and the industrial mindset of their
team are impressive. In light of their track record and the market potential,
this company will soon be an Austrian IPO candidate.”

Thomas Moser, Managing Partner at Pontis Capital, commented: “We have
been impressed with the progress EUCODIS Bioscience has made in
commercializing their experience in enzyme development. In addition, they
have established a proven technology for the directed evolution of enzymes
and have developed a unique expertise in manufacturing specialty enzymes.
This provides the right ingredients to make EUCODIS Bioscience a preeminent
supplier to the white biotechnology industry.”

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, customizes, manufactures, and markets
industrial enzymes.

EUCODIS Bioscience’ products help customers in the chemical,
pharmaceutical, and food and feed industries to make manufacturing processes
more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for
industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal
Health. Since 2009, the Company develops and markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by
Austrian and German institutional venture capital funds, founders, and
private investors. The Company is headquartered in Austria, Europe, with a
subsidiary in Germany.

    For more information, please visit http://www.eucodisbioscience.com

    Company contact EUCODIS Bioscience:
    Thomas Fischer, MBA
    CEO
    EUCODIS Bioscience
    Campus Vienna Biocenter II
    Viehmarktgasse 2 a/ 2 OG
    A-1030 Vienna
    AUSTRIA
    +43-1-8900804
    office@eucodisbioscience.com

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications

http://www.butschbacher.net

    +43-650-7844940
    office@butschbacher.net

SOURCE EUCODIS Bioscience


Source: newswire



comments powered by Disqus